Clinical Trial Update: Trabectedin and Irinotecan for Refractory Pediatric Sarcomas

View source ↗

Summary

Clinical trial update for pediatric refractory sarcomas exploring trabectedin in combination with irinotecan; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Irinotecan (Irinotecan)
• Trabectedin (trabectedin)

Snippet

Sponsor: Technical University of Munich | Conditions: Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma | Status: UNKNOWN